Regeneron (REGN) and Telix (TLX) to co-develop and co-commercialise next-gen radiopharmaceutical Therapies in a 50/50 cost and profit-sharing model; Telix to receive USD 40mln upfront and up to USD 2.1bln in milestones

Regeneron and Telix's joint development and commercialization of next-gen radiopharmaceuticals marks a significant strategic partnership in the biotechnology sector. The upfront payment coupled with milestone incentives suggests strong expectations for the therapies, which could impact their market valuation and signal confidence in the growth potential for both companies.